TLDR:
- Zenas BioPharma raised $200M in Series C funding for its inflammation and immunology-directed therapies.
- The funding round was led by SR One, NEA, Norwest Venture Partners, and Delos Capital, among others.
Zenas BioPharma, a Waltham, MA-based biopharmaceutical company, raised $200M in Series C funding for its inflammation and immunology-directed therapies. The round was led by SR One, NEA, Norwest Venture Partners, and Delos Capital, with participation from other investors. The funding will be used to advance ongoing mid- to late-stage clinical development programs for its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to inhibit B cell activity. The company, led by CEO Lonnie Moulder, is committed to developing and commercializing autoimmune therapeutics in areas of high unmet medical need. The obexelimab clinical programs include trials in IgG4-Related Disease, Multiple Sclerosis, Systemic Lupus Erythematosus, and Warm Autoimmune Hemolytic Anemia. Lonnie Moulder expressed gratitude for the support from investors as they advance the obexelimab development program across multiple autoimmune diseases.
